CAR T-cell therapy trials in relapsed/refractory CLL
| Study . | Product . | Sample size (enrolled/treated) . | Median age (years) . | Median prior lines of therapy . | ORR (%) . | CRR (%) . | Median PFS (months) . | mOS (months) . | Grade 3-5 CRS (%) . | Grade 3-5 neurotoxicity (%) . |
|---|---|---|---|---|---|---|---|---|---|---|
| Porter et al14 | CTL019 (tisagenlecleucel) | 23/14 | 66 | 5 | 57 | 28 | 7 | 29 | 43 | 7 |
| Frey et al16 | CTL019 (tisagenlecleucel) | 42/38 | 62 | 3.5 | 44 | 28 | 1.8 | 64 | 24 | 8 |
| Brentjens et al17 | 2nd-generation CD19 CAR T | 8/8 | 68 | 2-3 | 12 | 0 | Not reported | Not reported | 50 | Not reported |
| Siddiqi et al21 | JCAR017 (lisocabtagene-maraleucel) | 137/117 | 65 | 5 | 47 | 18 | 17.9 | 43.2 | 9 | 19 |
| Liang et al20 | JCAR014 | 49/49 (7 with prior Richter's transformation, 2 with current RT; 30 without ibrutinib and 19 with concurrent ibrutinib) | 61 | 5 | 70 | 17 | 8.9 | 25 | 14 | 27 |
| Study . | Product . | Sample size (enrolled/treated) . | Median age (years) . | Median prior lines of therapy . | ORR (%) . | CRR (%) . | Median PFS (months) . | mOS (months) . | Grade 3-5 CRS (%) . | Grade 3-5 neurotoxicity (%) . |
|---|---|---|---|---|---|---|---|---|---|---|
| Porter et al14 | CTL019 (tisagenlecleucel) | 23/14 | 66 | 5 | 57 | 28 | 7 | 29 | 43 | 7 |
| Frey et al16 | CTL019 (tisagenlecleucel) | 42/38 | 62 | 3.5 | 44 | 28 | 1.8 | 64 | 24 | 8 |
| Brentjens et al17 | 2nd-generation CD19 CAR T | 8/8 | 68 | 2-3 | 12 | 0 | Not reported | Not reported | 50 | Not reported |
| Siddiqi et al21 | JCAR017 (lisocabtagene-maraleucel) | 137/117 | 65 | 5 | 47 | 18 | 17.9 | 43.2 | 9 | 19 |
| Liang et al20 | JCAR014 | 49/49 (7 with prior Richter's transformation, 2 with current RT; 30 without ibrutinib and 19 with concurrent ibrutinib) | 61 | 5 | 70 | 17 | 8.9 | 25 | 14 | 27 |